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Background: The Medical Research Council (MRC) chronic dyspnea scale (6-point) is used
in different clinical conditions to grade breathlessness on daily activities. We have
previously shown that in patients with histologically documented usual interstitial
pneumonia/idiopathic pulmonary fibrosis (UIP/IPF), the MRC dyspnea scale is useful in
estimating disease severity. The aim of this study was to further investigate the usefulness
of the MRC scale in IPF as a marker of survival.
Methods: The records of 25 patients with histologically documented UIP/IPF were
retrospectively reviewed. Clinical parameters, pulmonary function tests, and arterial
blood gases at the time of diagnosis, as well as survival time were retrieved and recorded
for each patient. The impact of the different variables determined at diagnosis on survival
was examined using the Kaplan–Meier and uni- and multi-variate Cox-regression analyses.
Results: Among the baseline clinical and physiologic parameters determined at the time
of IPF diagnosis, the MRC score, the Tiffeneau index, and the total lung capacity were the
only significant and independent predictors of survival. In specific, a high MRC score, a high
Tiffeneau index, and a low total lung capacity at presentation were associated with
shorter survival.Elsevier Ltd. All rights reserved.
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MRC scale as a predictor of survival in IPF 587Conclusion: In accordance with the previous work, our results indicate that the Tiffeneau
index and total lung capacity (TLC) are the important determinants of survival in patients
with IPF. In addition, we show that the simple MRC chronic dyspnea score estimated at the
time of diagnosis is equally predictive of survival and may aid clinicians in assessing the
prognosis of new cases of IPF.
& 2007 Elsevier Ltd. All rights reserved.Introduction
In idiopathic pulmonary fibrosis (IPF), a combination of
inflammatory and fibrotic lung parenchymal damage leads to
the defects in lung mechanics and gas exchange which
manifest clinically with progressive exertional dyspnea, the
most prominent and disabling symptom in these patients.1–4
Since IPF carries a poor prognosis, early prediction of
survival is of considerable value for clinicians. Recent
studies have shown that among the noninvasive variables
used to estimate disease severity, the total lung capacity
(TLC) and forced vital capacity (FVC) are independent
predictors of IPF outcome.5–7 However, additional simple
clinical tools to estimate prognosis are useful, as not all
patients with IPF are fit to execute lung function testing
maneuvers.
The Medical Research Council (MRC) chronic dyspnea
scale is commonly used to grade breathlessness in
patients suffering from various clinical conditions.8–13 We
have previously shown that, in patients with IPF, the MRC
score is helpful in estimating disease severity, since the
score correlated with both physiologic and radiologic indices
of disease severity and extent.12
The aim of this study was to examine whether clinical and
physiologic parameters recorded during the diagnosis of IPF,
including the MRC chronic dyspnea score, can serve as
surrogate predictors of survival. We hypothesized that, in
addition to the lung function tests, the MRC index would be
tightly linked to survival.
Patients and methods
Subjects
This study was approved by the Institutional Ethics Commit-
tee of ‘‘Attikon’’ University Hospital, National and Kapo-
distrian University of Athens, Greece. Written informed
consent was obtained from each patient. We retrospectively
reviewed the records of 25 consecutive patients with IPF,
who were recruited from the respiratory outpatient clinic
between the years 2004 and 2007. Some of these patients
have been included in a previous study of our group.12 All
patients had IPF based on ATS/ERS diagnostic criteria and
lung biopsies obtained by video-assisted thoracoscopic
surgery, which showed usual interstitial pneumonia (UIP).4
Secondary causes of lung fibrosis were excluded: none of the
patients had a history of environmental or occupational
exposure, drug toxicity or connective tissue disease, as
documented by history, clinical and immunological tests.
Upon establishment of the diagnosis, all patients received
initially oral methylprednisolone (0.3mg/kg/d with subse-quent taper) and azathioprine (3mg/kg/d) for at least 3
months.4 One patient was treated with oral colchicine
(0.6mg/d) in addition to immunosuppressants.
Dyspnea
Dyspnea was assessed at presentation by the treating
physicians (EDM, ZD, SAP) using the self-administered
6-point MRC chronic dyspnea questionnaire consisting of
the following questions about perceived breathlessness: 0,
no dyspnea; 1, slight dyspnea (shortness of breath when
hurrying on the level or walking up a slight hill); 2, moderate
dyspnea (walks slower than people of the same age on the
level because of breathlessness); 3, moderately severe
dyspnea (stops because of breathlessness when walking at
own pace on the level); 4, severe dyspnea (stops for breath
after walking about 100 yards or after a few minutes on the
level); 5, very severe dyspnea (too breathless to leave the
house or breathless when dressing or undressing).8
Pulmonary function tests
Lung function tests were done during the diagnostic
approach and included forced expiratory volume during
the 1 s of expiration (FEV1), forced vital capacity (FVC),
FEV1/FVC (Tiffeneau) index, TLC, and single-breath carbon
monoxide diffusing capacity (DLCO). TLC was measured by
the helium dilution method with a Master Screen apparatus
(Erich Jaeger GmbH, Wuerzburg, Germany) and DLCO by the
single breathholding helium dilution method.14,15 Measure-
ments were expressed as percent of predicted normal
values.14,15 The arterial partial pressure for oxygen (PaO2)
and carbon dioxide (PaCO2) were also measured at rest in all
patients.
Survival
At the time of data acquisition for this study, 12/25 patients
had succumbed to IPF. All deaths were directly attributable
to the disease, a fact verified by death certificates. The
13/22 patients still alive during reporting of this work were
censored for survival analysis.
Statistics
Normally and not normally distributed data are presented as
mean7SEM or median (interquartile range), respectively.
Survival is given as median or mean (95% confidence
interval); mean was used when median survival could not
be calculated (e.g. when more than half of the observations
were censored). n indicates the number of observations.
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Table 1 Data acquired during the study.
No. Age (yr) Sex Smoking
(pck-yr)
Symptoms
(mos)
MRC Survival
(mos)
FEV1 (%
predicted)
FVC (%
predicted)
FEV1/FVC (%
predicted)
TLC (%
predicted)
DL (%
predicted)
PaO2
(mmHg)
PaCO2
(mmHg)
1 60 1 0 60 3 16 75 64 92 50 22 70 35
2 70 1 20 12 1 78 97 80 93 62 54 78 45
3 70 1 0 14 2 59 61 60 78 52 52 62 35
4 56 1 45 60 2 80 63 56 89 52 48 71 37
5 55 0 0 10 1 97 97 94 87 74 80 80 37
6 49 0 0 18 2 52 97 87 90 68 32 77 30
7 43 0 60 20 2 69 77 77 84 74 38 76 31
8 67 0 0 9 1 90 90 90 81 68 56 88 38
9 64 0 0 6 1 68 89 87 87 70 55 84 37
10 69 1 60 4 1 68 94 85 84 69 74 74 39
11 63 0 0 12 4 6 77 67 94 51 35 73 30
12 64 1 40 60 3 8 70 55 100 46 43 72 39
13 62 0 0 30 2 9 87 75 95 55 50 75 38
14 41 1 2 30 2 85 92 84 91 74 70 87 42
15 71 0 0 21 2 100 78 85 75 96 54 75 38
16 80 1 15 12 1 33 92 77 88 61 61 89 43
17 60 1 10 6 3 70 70 56 98 90 63 72 38
18 70 1 15 24 3 76 61 68 79 52 51 66 40
19 73 1 50 18 4 54 57 64 89 49 31 72 38
20 64 1 0 12 2 37 83 69 94 53 46 69 39
21 73 0 0 6 1 50 76 65 97 51 21 78 41
22 60 0 0 20 5 7 69 56 100 87 78 49 28
23 67 0 0 8 2 53 78 75 91 67 45 70 39
24 80 0 0 12 3 3 84 81 93 65 36 77 43
25 68 0 0 15 3 46 86 78 92 67 24 57 42
MRC, Medical Research Council dyspnea score; FEV1, forced expiratory volume during the 1 s of expiration; FVC, forced vital capacity; TLC, total lung capacity; DL, single-breath carbon
monoxide diffusing capacity; PaO2, arterial partial oxygen pressure; PaCO2, arterial partial carbon dioxide pressure.
Patients that succumbed to IPF; the rest of survival data represent censored observations. E.D
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MRC scale as a predictor of survival in IPF 589Survival analysis was done in two ways: (i) Kaplan–Meier
analysis with log-rank tests for comparisons between groups
was performed after splitting the study cohort into groups
according to the variable under examination for impact on
survival. When the variable was not categorical (such as e.g.
sex or MRC), arbitrary cut-off points were used. In the case
of lung function tests, the limits of normal were used as cut-
off points. In all other cases, median values were used to
divide the study cohort in two groups. (ii) Simple (uni-
variate) and multiple (multivariate) Cox regression (risk
ratio) analyses were employed. Probability values less than
0.05 were considered statistically significant. All analyses
were done using the Statistical Package for the Social
Sciences Software Version 11.0 (SPSS, Chicago, IL).0.5
0.0
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iv
a
n = 25
mean = 65(51-80) mos
median = 78(48-108) mos
0 12 24 35 48 60 72 84 96
months post-diagnosis
Figure 1 Survival of 25 patients with histologically documen-
ted UIP/IPF. Twenty-five patients with histologically documen-
ted UIP/IPF were followed till death (uncensored: n ¼ 12) or
reporting of the study (censored: n ¼ 13). Shown are cumula-
tive Kaplan–Meier survival plot, sample size (n), and survival
[mean and median (95% confidence interval)].Results
The demographic, clinical, and functional characteristics of
the study population at the time of IPF diagnosis are given in
Tables 1 (raw data) and 2 (summarized data).
At the time of reporting of this study, 12 patients had
succumbed to IPF while 13 patients were still alive (Table 1
and Figure 1). Initially, we examined whether any of the
parameters determined at diagnosis were linked to survival
using Kaplan–Meier analysis. In this regard, age, sex,
smoking status and exposure, symptom duration before
diagnosis, and arterial blood partial gas tensions were not
associated with survival (Table 2). On the contrary, patients
with higher MRC scores at diagnosis exhibited significantly
shorter survival (Figure 2A). In addition, patients with low
FVC (o80% predicted), high FEV1/FVC ratio (X90% pre-Table 2 Summary of baseline characteristics of 25 patients wit
using univariate Cox-regression analysis.
Trend
Age (years)y 6472
Sex (male/female) 12/13
Smoking (never/ex-/current) 15/5/5
(pack-years)y 1374
Symptom duration (months)yy 14 (10–21)
MRC dyspnea scoreyy 2 (1–3)
Lung function tests (% predicted)y
FEV1 8072
FVC 7372
FEV1/FVC 9071
TLC 6473
DLCO 4973
Arterial blood gases (mmHg)y
PaO2 7472
PaCO2 3871
yData presented as mean7standard error of mean.
yyData presented as median (interquartile range).
*Significant predictors of survival among baseline features of study c
#Log-rank test for comparison of survival between male and female
analysis.
MRC, Medical Research Council; FEV1, forced expiratory volume durin
capacity; DLCO, single-breath carbon monoxide diffusing capacity;
carbon dioxide pressure; RR, risk ratio; CI, confidence interval.dicted), and low TLC (o65% predicted) at presentation,
experienced shorter survival (Figure 2B–D). There was no
apparent link between FEV1 and DLCO at presentation and
survival.h histologically documented IPF and their impact on survival
P RR (95% CI)
0.800 1.008 (0.951–1.068)
0.278]
0.927]
0.597 0.992 (0.961–1.023)
0.167 1.022 (.991–1.053)
0.007* 2.290 (1.257–4.170)
0.628 0.989 (0.947–1.034)
0.046* 0.950 (0.904–0.999)
0.011* 1.162 (1.035–1.304)
0.032* 0.935 (0.879–0.994)
0.209 0.975 (0.936–1.015)
0.167 0.951 (0.886–1.021)
0.170 0.898 (0.770–1.047)
ohort.
patients or never/former/current smokers using Kaplan–Meier
g the 1 s of expiration; FVC, forced vital capacity; TLC, total lung
PaO2, arterial partial oxygen pressure; PaCO2, arterial partial
ARTICLE IN PRESS
Figure 2 Baseline parameters at IPF diagnosis that are linked
to survival using Kaplan–Meier analysis. Twenty-five patients
with histologically documented UIP/IPF were clinically and
functionally assessed during diagnosis and were followed till
death (uncensored: n ¼ 12) or reporting of the study (censored:
n ¼ 13). (A) Patients with higher initial MRC scores experienced
shorter survival. (B) Patients with FVCo80% (C), FEV1/
FVCX90% (D), and TLCo65% of predicted values exhibited
significantly shorter survival. Shown are cumulative Kaplan–
Meier survival plots, sample sizes (n), mean (95% confidence
interval) survival times, and log-rank test probability values (P)
for comparison between groups. IPF, idiopathic pulmonary
fibrosis; MRC, Medical Research Council. FEV1, forced exhaled
volume in the first second of exhalation; FVC, forced vital
capacity; TLC, total lung capacity.
Table 3 Impact of MRC, FVC, FEV1/FVC, and TLC on
survival using multivariate Cox regression analysis.
P RR (95% CI)
MRC dyspnea score 0.022* 2.394 (1.133–5.058)
Lung function tests (% predicted)
FVC 0.033 1.045 (0.956–1.142)
FEV1/FVC 0.017* 1.246 (1.039–1.494)
TLC 0.024* 0.929 (0.871–0.990)
*Significant predictors of survival among baseline features of
study cohort.
MRC, Medical Research Council; FEV1, forced expiratory
volume during the first second of expiration; FVC, forced
vital capacity; TLC, total lung capacity; RR, risk ratio; CI,
confidence interval.
E.D. Manali et al.590On univariate Cox-regression analysis (Table 2), low initial
FVC and TLC, and high initial FEV1/FVC ratio significantly
and negatively impacted survival, in accord with the
Kaplan–Meier analyses detailed above. Importantly, the
MRC score was the only purely clinical-derived indicator
independently predicting survival. We then entered these
variables (FVC, FEV1/FVC index, TLC, and MRC score) in
multiple Cox regression analyses to generate a linear model.
FVC did not emerge as an independent prognosticator of
outcome in IPF. However, along with the FEV1/FVC index and
TLC, the MRC score proved to be an independent predictor
of survival (Table 3). Collectively these results indicate that
the MRC score recorded at diagnosis of IPF may serve as an
independent predictor of survival, along with functional
variables, such as the FEV1/FVC index and TLC.Discussion
In this study we assessed dyspnea at diagnosis in 25 patients
with histology-proven UIP/IPF, using a simple self-reported
questionnaire, the MRC chronic dyspnea score.8 We also
measured the physiologic parameters commonly used to
assess disease severity, including the lung function tests and
arterial blood gases. In our patients with IPF, the FEV1/FVC
index and TLC could independently predict survival. In
addition, the MRC score was the only pure clinical
parameter that could serve as an independent predictor of
survival. We have previously shown that in patients with IPF,
the MRC score determined at presentation is a marker of
disease severity.12 The present study suggests that this
simple clinical measurement can also be used as a marker of
survival in IPF patients.
We have previously shown that in patients with IPF, the
MRC index determined at diagnosis is intimately associated
with the degree of disease severity, independently so with
the FEV1/FVC index and TLC.
12 In the present study we have
found that these indices of disease severity that are
independently linked to the MRC score were also predictive
of survival. Hence, not only the MRC score can predict
survival in patients suffering from IPF, but so can the
baseline parameters intimately associated with this index.
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MRC scale as a predictor of survival in IPF 591IPF is a chronic and progressive interstitial lung disease
that uniformly results in severe disability and death.1–3
Virtually every affected person will develop breathlessness
at rest or with minimal exertion as the disease ad-
vances.13,16,17 Previous studies that attempted to predict
prognosis in IPF and other fibrogenic interstitial pneumonias
have focused on baseline physiologic, radiographic, and
clinical parameters and have yielded inconsistent or contra-
dictory results.18–23 Other more elaborate scores identified
the histopathologic pattern as an important baseline
predictor of survival.24–27 However, the risks of biopsy are
not negligible, and nowadays there is a tendency to rely
more on a constellation of clinical and imaging findings
indicative of UIP/IPF, obviating biopsy.28,29 In addition,
clinicians facing patients with UIP/IPF are in need of simpler
and safer approaches to predict survival. Herein we show
that the MRC index can be used for this purpose.
As far as the population of our study is concerned, all of
our patients had histologically based diagnoses of UIP/IPF,
meaning that heterogeneity of pathological types of
interstitial lung disease could not have influenced our
findings. Our patients presented with age, gender, pulmon-
ary function, and DLCO similar to study cohorts reported
by others.6,7 Differences were seen in smoking habits,
FEV1/FVC, and treatment. Most of our patients were
never- or ex- smokers, presented with a more restrictive
pattern of disease, and had mostly been treated with
azathioprine plus prednisone. Most importantly however,
their mean age (6472years) was not outside the transplant
age-line.30
In our IPF patients, the MRC score assessed at diagnosis of
IPF was the only purely clinical predictor of survival.
Compared to previously reported scores for IPF progression,
such as the clinical, radiographic and physiologic (CRP)
score, the MRC score is by far the simplest.31–33 Previous
early studies provided short-term validation for CRP, but
longitudinal studies suggested significant variability.31,34
This suggests the need to extend the use of the MRC score
in larger prospective trials in IPF patients. Although our
results are based on a retrospective analysis of a relatively
small number of patients, the present study was done on a
solid group of biopsy proven UIP/IPF patients and all deaths
were IPF-related.
It is a common belief that the predictive value of easily
measured, safely performed and reliable clinical and
physiologic parameters could improve the care of patients
with IPF in several ways. It could allow clinicians to make a
accurate prognosis and facilitate a timely referral of
patients with limited prognosis for lung transplantation.7,34
In this regard, it was recently shown that lung transplanta-
tion is the only therapy to prolong survival in advanced IPF.
However, a major factor leading to increased death rates
among this patient group on the transplant waiting list is
referral delay due to a lack of validated prognostic
measures.35,36 In this study we show the usefulness of the
MRC chronic dyspnea scale in predicting the survival of
patients suffering from IPF relatively at the early course of
the disease. Hence the MRC index may be useful in patient
selection for timely referral for transplantation.
In conclusion, our data indicate that the MRC index is not
only a good indicator of disease severity, but also of survival
in IPF. A larger prospective study is still needed to betterelucidate the relationship between physiological changes,
survival, and the MRC score in UIP/IPF patients.Competing interest statement
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